# Kenvue

Type: Company (KVUE)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/kenvue
Canonical HTML page: https://gethealthbrief.com/entity/kenvue

## Recent coverage (3 stories)

### Over 500 Tylenol suits revived: Prenatal care guidelines under microscope
2026-07-25 19:57:02 · Sentiment: Negative · Impact: 7/10 · Sources: 2

The legal reinstatement of Tylenol-autism lawsuits pressures healthcare providers to reconcile conflicting evidence on acetaminophen safety in pregnancy, potentially altering clinical guidance, patient counseling, and EHR decision support.
Full story: https://gethealthbrief.com/story/tylenol-autism-lawsuits-revived-health

### J&J’s $100B Revenue Runway: How Next-Gen Drugs Are Plugging the Stelara Gap
2026-07-20 00:11:51 · Sentiment: Positive · Impact: 7/10 · Sources: 2

J&J’s Q2 2026 earnings beat underscores a successful pivot away from Stelara’s $10B peak. New oncology and immunology drugs are powering growth, with full-year revenue now expected to top $100B. For healthcare stakeholders, this signals pipeline resilience and a defensive stock offering amid sector headwinds.
Full story: https://gethealthbrief.com/story/jnj-100b-pharma-pipeline-stelara-gap-health

### BofA Lifts Johnson & Johnson Price Target on Robust Pipeline Momentum
2026-03-12 08:11:39 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bank of America has raised its price target for Johnson & Johnson (JNJ), citing a strengthened outlook for the company's pharmaceutical and MedTech pipelines. The upgrade reflects growing investor confidence in JNJ's post-Kenvue strategy, which prioritizes high-margin innovation in oncology, immunology, and surgical robotics.
Full story: https://gethealthbrief.com/story/bofa-raises-jnj-price-target-pipeline-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.